Roger Pomerantz - 10 Aug 2022 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)

Role
Director
Signature
/s/ Daniel Chevallard, as Attorney-in-Fact
Issuer symbol
VIRX
Transactions as of
10 Aug 2022
Net transactions value
$0
Form type
4
Filing time
11 Aug 2022, 19:01:48 UTC
Previous filing
10 Jun 2022
Next filing
29 Aug 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIRX Stock Option (Right to Buy) Award $0 +30,282 $0.000000 30,282 10 Aug 2022 Common Stock 30,282 $3.69 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One twelfth (1/12th) of the shares subject to the Option shall vest each month following the Vesting Commencement Date (as defined below), on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), or if earlier one hundred percent (100%) of the shares subject to the Option shall vest on the date of the Company's next annual stockholder meeting, in each case subject to the Participant continuing to be a Service Provider (as defined in the Company's 2021 Equity Incentive Plan) through each such date. The Vesting Commencement Date is July 29, 2022.